Baker Brothers Life Sciences Capital (GP), LLC Insider Trading $GEVA SYNAGEVA BIOPHARMA CORP
Get free email notifications about insider trading for Baker Brothers Life Sciences Capital (GP), LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Baker Brothers Life Sciences Capital (GP), LLC. Baker Brothers Life Sciences Capital (GP), LLC is 10% Owner in HERON THERAPEUTICS, INC. /DE/ ($HRTX) and 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and 10% Owner in PHARMACYCLICS INC ($PCYC) and 10% Owner in VIROPHARMA INC ($VPHM) and Director in SYNAGEVA BIOPHARMA CORP ($GEVA) and 10% Owner in ADOLOR CORP ($ADLR) and Director in Ardea Biosciences, Inc./DE ($IBPI) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in AUXILIUM PHARMACEUTICALS INC ($AUXL) and 10% Owner in Ocera Therapeutics, Inc. ($TZYM).
Baker Brothers Life Sciences Capital (GP), LLC in SYNAGEVA BIOPHARMA CORP
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Baker Brothers Life Sciences Capital (GP), LLC: Director
Holdings: 5,077,676 shares
Latest Transaction: Jan 09 2012
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Baker Brothers Life Sciences Capital (GP), LLC in SYNAGEVA BIOPHARMA CORP
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADLR, IBPI, AUXL, BCRX, GHDX, HRTX, INCY, TZYM, PCYC, SGEN, GEVA, VPHM
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Grant | A | 25.18 | 1,077,225 | 27,124,526 | 5,077,676 | 4 M to 5.1 M (+26.93 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Grant | A | 0.00 | 3,253,761 | 0 | 4,000,451 | 746.7 K to 4 M (+435.76 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Grant | A | 0.00 | 251,971 | 0 | 746,690 | 494.7 K to 746.7 K (+50.93 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Grant | A | 0.00 | 244,194 | 0 | 494,719 | 250.5 K to 494.7 K (+97.47 %) |
| Jul 05 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Buy | J | 0.00 | 9,852 | 0 | 1,252,625 | 1.2 M to 1.3 M (+0.79 %) |
Page: 1